Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogene-modified T Cells (IgT) in Ovarian Cancer
NCT03184753Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of OC-IgT cells in ovarian cancer, sponsored by Shenzhen Geno-Immune Medical Institute. Started May 2025; status: terminated.
02
Drugs
OC-IgT cells
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03184753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03184753.